Vivos Therapeutics' VidaSleep™ oral appliance receives CMS approval, expanding treatment options for obstructive sleep apnea and snoring.
Quiver AI Summary
Vivos Therapeutics, Inc. has announced that its VidaSleep™ oral appliance, equipped with FDA-cleared Unilateral Bite Block technology, has received approval from the Centers for Medicare & Medicaid Services (CMS) for treating mild to moderate obstructive sleep apnea (OSA) and snoring in adults. This approval allows Vivos to expand its market presence and potentially reach millions of Medicare beneficiaries seeking alternatives to CPAP machines. With the VidaSleep™ joining the already Medicare-covered mmRNA® device, Vivos is uniquely positioned with two differentiated and patented appliances to address OSA's root causes. This dual offering aims to serve a broad segment of the sleep therapy market, facilitating better access to treatment options for patients while maintaining strong gross profit margins for providers. The press release highlights the pressing need for effective OSA solutions, as a significant portion of the population remains undiagnosed, urging healthcare professionals to consider these advanced, noninvasive therapies.
Potential Positives
- The VidaSleep™ oral appliance has received approval from the CMS PDAC for the treatment of mild to moderate OSA and snoring, enhancing its market potential.
- This approval positions Vivos as the only company with two Medicare-covered oral appliances, potentially increasing its competitive advantage and market presence.
- The dual-PDAC approval allows Vivos to serve a wider range of patients across the estimated $36 billion sleep therapy market, including Medicare and commercial payers, which may drive revenue growth.
- The approval is expected to incentivize private insurers to cover Vivos' appliances, broadening access and adoption among healthcare providers and patients.
Potential Negatives
- Concerns regarding the efficacy of the VidaSleep™ device, as some patients may not achieve the desired results from using Vivos’ products.
- Potential regulatory scrutiny and adverse publicity in the sleep apnea diagnosis and treatment sector could negatively impact the company's reputation.
- The company may face challenges in securing additional financing and maintaining its Nasdaq listing, which poses risks for ongoing operations.
FAQ
What is the VidaSleep™ oral appliance?
The VidaSleep™ oral appliance is a device approved for treating mild to moderate obstructive sleep apnea (OSA) and snoring in adults.
How does the VidaSleep™ device work?
It utilizes Vivos’ patented Unilateral Bite Block technology to improve airway patency and effectively address the root causes of OSA.
What does the PDAC approval mean for Vivos Therapeutics?
PDAC approval expands Medicare coverage for the VidaSleep™ device, increasing accessibility and market potential for Vivos and its products.
Who can benefit from the VidaSleep™ oral appliance?
The device is designed for adults with mild to moderate OSA, providing an alternative to CPAP machines and invasive treatments.
What is Vivos Therapeutics’ mission?
Vivos Therapeutics aims to promote sleep wellness and health by offering innovative, non-invasive solutions for people suffering from OSA and snoring.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$VVOS Hedge Fund Activity
We have seen 13 institutional investors add shares of $VVOS stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STRATEGIC WEALTH INVESTMENT GROUP, LLC removed 100,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $429,000
- ENVESTNET ASSET MANAGEMENT INC added 38,873 shares (+inf%) to their portfolio in Q1 2025, for an estimated $110,788
- VANGUARD GROUP INC added 32,055 shares (+303.0%) to their portfolio in Q1 2025, for an estimated $91,356
- OMERS ADMINISTRATION CORP removed 25,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $107,250
- SABBY MANAGEMENT, LLC removed 20,502 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $87,953
- TWO SIGMA INVESTMENTS, LP removed 20,482 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $87,867
- ROYAL BANK OF CANADA added 18,000 shares (+450000.0%) to their portfolio in Q1 2025, for an estimated $51,300
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
LITTLETON, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced that its VidaSleep™ oral appliance , featuring Vivos’ patented and U.S. Food and Drug Administration (FDA) cleared Unilateral Bite Block technology, has been approved by the Centers for Medicare & Medicaid Services (CMS) Pricing, Data Analysis and Coding (PDAC) contractor for the treatment of mild to moderate OSA and snoring in adults.
The VidaSleep™ Device
With over 80% of OSA cases in the United States undiagnosed and an estimated 80 million Americans affected, Vivos’ comprehensive portfolio of OSA treatments is poised to capture a significant share of the underpenetrated sleep therapy market. Medicare coverage opens the door to commercial payers that follow CMS guidelines, amplifying Vivos’ addressable market.
With this approval, VidaSleep™ joins the Vivos mmRNA® on the PDAC list of covered oral appliances, unlocking access for millions of Medicare beneficiaries seeking clinically advanced alternatives to CPAP machines or invasive surgeries. The dual-PDAC approval positions Vivos as the only company with two Medicare-covered oral appliances featuring differentiated and patented technologies designed to address the root causes of OSA while offering patients two distinct pathways and price points for therapy. The VidaSleep™ oral appliance features Vivos’ proprietary Unilateral Bite Block technology, while the mmRNA appliance is part of the FDA-cleared Vivos CARE product line for moderate to severe OSA cases in adults and children.
“The PDAC approval of VidaSleep is another milestone achievement for Vivos, strategically positioning us to significantly augment our presence in the value-based care segment of the sleep apnea market,” said Kirk Huntsman, CEO and Chairman of Vivos Therapeutics . “While mmRNA® remains our premium solution for complex cases, VidaSleep delivers positive clinical outcomes through an optimized design that maximizes accessibility—proving that 'cost-effective' doesn't mean 'compromise.' This dual-device approach allows us to serve every tier of the estimated $36 billion sleep therapy market, from Medicare beneficiaries to commercial payers, while maintaining our compelling gross profit margins. Just as importantly, it empowers thousands more clinicians to adopt our technology, knowing they now have multiple reimbursed options to match patient needs.”
Commercial & Clinical Advantages
PDAC approval not only benefits Medicare patients but also incentivizes private insurers to cover Vivos’ appliances. The VidaSleep™ device, like Vivos’ mmRNA® device, is designed for use as a standalone therapy or adjunct to CPAP, offering flexibility for providers and patients. VidaSleep™ offers a compelling value proposition, combining the clinical advantages of Vivos’ proprietary technology with a cost-effective price point designed to expand accessibility. Its streamlined design and efficient manufacturing process allow Vivos to deliver high-impact therapy at a budget-conscious rate—without compromising efficacy or quality—increasing opportunities for broader adoption across Medicare and commercial insurance networks while preserving strong gross margins for the healthcare providers nationwide who can now deliver these solutions with greater confidence in insurance reimbursement.
Sleep Apnea: A Silent Crisis
OSA is linked to severe comorbidities, including heart disease, stroke, and dementia, yet remains grossly underdiagnosed. Vivos’ oral appliances represent a paradigm shift by addressing the structural root causes of OSA, with peer-reviewed studies demonstrating significant improvements in airway patency and symptom resolution, including the recently announced landmark study published in the European Journal of Pediatrics.
About Vivos Therapeutics
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ Complete Airway Repositioning and/or Expansion (CARE) devices are the only oral appliances cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices.
Obstructive sleep apnea (OSA) affects over 1 billion people worldwide, yet 90% remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep issue—it’s closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, solutions are often mechanistic and fail to address the root causes of OSA.
Vivos Therapeutics, founded in 2016 and based in Littleton, CO, is changing this. Through innovative technology, education, and collaborations with or acquisitions of functional medicine doctors, and sleep specialists, Vivos is empowering healthcare providers to more thoroughly address the complex needs of patients suffering with OSA.
Vivos’ portfolio of cutting-edge oral appliances offer a proprietary, clinically effective OSA solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life . For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, including statements of the Company’s management and other parties made herein, contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “would”, “should”, “expects”, “projects”, “opportunity”, “potential,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”, “aim” and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, those relating to the anticipated benefits to Vivos of the PDAC approval for the VidaSleep™ device as described herein. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Readers are cautioned that actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to successfully implement sales, marketing and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) the risk that published study data may not be predictive of results with Vivos treatment for all patients, (iv) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (v) the risk that Vivos may be unable to secure additional financing when needed, if at all, or maintain its Nasdaq listing, (vi) market and other conditions that could impact Vivos’ business or ability to obtain financing (including whether insurance will cover the cost of Vivos treatment), and (vii) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Media Inquiries:
Karla Jo Helms
JOTO PR™
727-777-4629
jotopr.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ec018d95-bc0e-49fd-a261-23dddbef7a49